1,25-Dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter

Atherosclerosis

Volumn 204, Issue 1, 2009, Pages 85-89

  Cardus, Anna ^a   Panizo, Sara ^a   Encinas, Mario ^a   Dolcet, Xavier ^a   Gallego, Carme ^b   Aldea, Martí ^b   Fernandez, Elvira ^a   Valdivielso, Jose M ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b UNIVERSITY OF LLEIDA   (Spain)

Author keywords

Gene promoter; VEGF; Vitamin D; Vitamin D response element

Indexed keywords

CALCITRIOL; VASCULOTROPIN; VITAMIN D RECEPTOR;

AORTA MEDIA; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE; VITAMIN D RESPONSIVE ELEMENT;

BASE SEQUENCE; CALCITRIOL; CELL LINE; GENES, REPORTER; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROMOTER REGIONS, GENETIC; RECEPTORS, CALCITRIOL; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 62849083876     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.08.020     Document Type: Article

References (35)

1. 3 and its analogs on growth control and tumorigenesis. Front Biosci 6 (2001) D820-D848
2. Craver L., Marco M.P., Martinez I., et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant 22 (2007) 1171-1176
3. Marco M.P., Craver L., Betriu A., et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int 63 (2003) S111-S114
4. Carlberg C. Mechanisms of nuclear signaling by vitamin-D-3-interplay with retinoid and thyroid-hormone signaling. Eur J Biochem 231 (1995) 517-527
5. Ferrara N., and Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161 (1989) 851-858
6. Maharaj A.S.R., and D'Amore P.A. Roles for VEGF in the adult. Microvasc Res 74 (2007) 100-113
7. Schrijvers B.F., Flyvbjerg A., and De Vriese A.S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65 (2004) 2003-2017
8. Cardus A., Parisi E., Gallego C., et al. 1,25-Dihydroxyvitamin D-3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 69 (2006) 1377-1384
9. Lin R., Amizuka N., Sasaki T., et al. 1 Alpha,25-dihydroxyvitamin D-3 promotes vascularization of the chondro-osseous junction by stimulating expression of vascular endothelial growth factor and matrix metalloproteinase 9. J Bone Miner Res 17 (2002) 1604-1612
10. Levine M.J., and Teegarden D. 1 alpha,25-dihydroxycholecalciferol increases the expression of vascular endothelial growth factor in C3H10T1/2 mouse embryo fibroblasts. J Nutr 134 (2004) 2244-2250
11. Yamamoto T., Kozawa O., Tanabe K., et al. 1,25-Dihydroxyvitamin D-3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase. Arch Biochem Biophys 398 (2002) 1-6
12. Das P.M., Ramachandran K., vanWert J., et al. Chromatin immunoprecipitation assay. Biotechniques 37 (2004) 961-969
13. Carlberg C., Bendik I., Wyss A., et al. 2 nuclear signaling pathways for vitamin-D. Nature 361 (1993) 657-660
14. Sanchez-Martinez R., Castillo A.I., Steinmeyer A., et al. The retinoid X receptor ligand restores defective signalling by the vitamin D receptor. EMBO Rep 7 (2006) 1030-1034
15. Schrader M., Nayeri S., Kahlen J.P., et al. Natural vitamin-D-3 response elements formed by inverted palindromes-polarity-directed ligand sensitivity of vitamin-D-3 receptor retinoid-X receptor heterodimer-mediated transactivation. Mol Cell Biol 15 (1995) 1154-1161
16. Yasmin R., Williams R.M., Xu M., et al. Nuclear import of the retinoid X receptor, the vitamin D receptor, and their mutual heterodimer. J Biol Chem 280 (2005) 40152-40160
17. Liu M., and Freedman L.P. Transcriptional synergism between the vitamin D3 receptor and other nonreceptor transcription factors. Mol Endocrinol 8 (1994) 1593-1604
18. Kerry D.M., Dwivedi P.P., Hahn C.N., et al. Transcriptional synergism between vitamin D-responsive elements in the rat 25-hydroxyvitamin D-3 24-hydroxylase (CYP24) promoter. J Biol Chem 271 (1996) 29715-29721
19. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (1998) S112-S119
20. Muntner P., Hamm L.L., Kusek J.W., et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Internal Med 140 (2004) 9-17
21. Tatematsu S., Wakino S., Kanda T., et al. Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 18 (2007) 741-749
22. Teng M., Wolf M., Lowrie E., et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349 (2003) 446-456
23. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16 (2005) 1115-1125
24. Tentori F., Hunt W.C., Stidley C.A., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70 (2006) 1858-1865
25. Melamed M.L., Eustace J.A., Plantinga L., et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 70 (2006) 351-357
26. Shoji T., Shinohara K., Kimoto E., et al. Lower risk for cardiovascular mortality in oral 1 alpha-hydroxy vitamin D-3 users in a haemodialysis population. Nephrol Dial Transplant 19 (2004) 179-184
27. Wolf M., Shah A., Gutierrez O., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72 (2007) 1004-1013
28. Martins D., Wolf M., Pan D., et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States-data from the Third National Health and Nutrition Examination Survey. Arch Internal Med 167 (2007) 1159-1165
29. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol: Cell Physiol 280 (2001) C1375-C1386
30. Asahara T., Takahashi T., Masuda H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18 (1999) 3964-3972
31. Szmitko P.E., Fedak P.W.M., Weisel R.D., et al. Endothelial progenitor cells-new hope for a broken heart. Circulation 107 (2003) 3093-3100
32. Rodriguez-Ayala E., Yao Q., Holmen C., et al. Imbalance between detached circulating endothelial cells and endothelial progenitor cells in chronic kidney disease. Blood Purif 24 (2006) 196-202
33. Hill J.M., Zalos G., Halcox J.P.J., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
34. Alon T., Hemo I., Itin A., et al. Vascular endothelial growth-factor acts as a survival factor for newly formed retinal-vessels and has implications for retinopathy of prematurity. Nat Med 1 (1995) 1024-1028
35. Yla-Herttuala S., Rissanen T.T., Vajanto I., et al. Vascular endothelial growth factors-biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49 (2007) 1015-1026